Facebook LinkedIn Twitter YouTube
Qu Biologics Inc.
Qu Biologics is a clinical stage biotechnology company developing Site Specific Immunomodulators (SSI), a novel class of immunotherapies designed to stimulate an innate immune response in targeted organs to reverse the immune dysregulation underlying many important diseases including cancer, inflammatory bowel disease, infection, and inflammatory lung diseases. Qu has completed four Phase 2 studies in lung cancer, Crohn’s disease, and ulcerative colitis. Qu’s 5th Phase 2 study is underway in early-stage colon cancer, with two additional upcoming Phase 2 randomized placebo-controlled studies in late-stage colon cancer and immunosenescence.
Queen’s University
We stand on a strong history of scholarship, discovery, and innovation.
Our education transforms Queen’s students. Our diversity enriches the community. Our research changes the world.
Together, we are tackling humanity’s greatest challenges.
Research Manitoba
Research Manitoba is Manitoba’s provincial research agency that promotes, supports, and coordinates the funding of research excellence in health, natural and social sciences, engineering, and the humanities in Manitoba. We cultivate local talent/workforce development of highly qualified personnel by investing in trainees and early career researchers and foster strategic partnerships to bolster innovation in the province. Beyond our funding programs, there are other ways in which Research Manitoba contributes to the research ecosystem. One major initiative is the Research Improvements Through Harmonization in Manitoba (RITHIM) program. RITHIM will streamline and harmonize health research ethics, privacy, and institutional impact reviews to create a more efficient and transparent process for health research approvals in Manitoba.